Skip to main navigation Skip to search Skip to main content

Breathomics to monitor interstitial lung disease associated with systemic sclerosis

  • Thibault Massenet*
  • , Judith Potjewijd
  • , Rachid Tobal
  • , Fanny Gester
  • , Delphine Zanella
  • , Monique Henket
  • , Makon Sébastien Njock
  • , Thibaut Dejong
  • , Gregory Gridelet
  • , Laurie Giltay
  • , Françoise Guissard
  • , Béatrice André
  • , Clio Ribbens
  • , Renaud Louis
  • , Pieter Van Paassen
  • , Julien Guiot
  • , Pierre Hugues Stefanuto
  • *Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Asthma exacerbations in people treated with mepolizumab result in less peak expiratory flow reduction than placebo but similar symptom scores. Symptoms recover slower, indicating these exacerbations may be less prednisolone responsive.
Original languageEnglish
Article number00175-2024
JournalERJ Open Research
Volume10
Issue number4
DOIs
Publication statusPublished - 16 Sept 2024

Fingerprint

Dive into the research topics of 'Breathomics to monitor interstitial lung disease associated with systemic sclerosis'. Together they form a unique fingerprint.

Cite this